Arcutis Biotherapeutics, Inc. Net Income Loss

• Arcutis Biotherapeutics, Inc. showed an increase of +88.5% in Net Income Loss from 2024 to 2025.
• This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Arcutis Biotherapeutics, Inc.'s Net Income Loss has grown by 16.2%.
• Historical annual values: Fiscal year 2025: -$16.14 million | Fiscal year 2024: -$140.04 million | Fiscal year 2023: -$262.14 million | Fiscal year 2022: -$311.46 million | Fiscal year 2021: -$206.36 million | Fiscal year 2020: -$135.68 million | Fiscal year 2019: -$42.00 million | Fiscal year 2018: -$19.26 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026